I’m excited to be part of this community! Looking forward to connecting with you all, learning new things, and sharing ideas. Thanks for having me here. Looking forward to growing together! 😊

Online, CJC-1295 often gets one chart and one “schedule.” In research talk, the first fork is usually different: with DAC vs without DAC (sometimes discussed alongside Mod GRF 1-29-style short-acting forms). Plain English CJC-1295 is studied as a GHRH-pathway research peptide (growth-hormone–releasing hormone related signaling). DAC (Drug Affinity Complex) is a modification discussed because it can extend how long the molecule stays in circulation compared with shorter-acting analogs. That half-life / duration difference is why frequency conversations in papers and reviews often split by form — not because one internet calendar fits every vial label. Evidence labels (be honest) - Mechanistic / pharmacology framing: GHRH-pathway signaling; DAC discussed for prolonged presence - Human data: exists in limited clinical/research contexts for related GHRH analogs — not the same as “copy this forum schedule” - Preclinical / early literature: used to explore GH-axis signaling; do not treat animal or early findings as a personal protocol - Anecdotal / community charts: weakest evidence tier for timing claims Important limitation “With DAC” vs “without DAC” is an educational distinction about duration framing. It is not personalized medical dosing advice. Published research context ≠ a recommendation to use any amount, route, or schedule. Practical takeaway When someone posts a CJC “timing chart,” ask: 1. Which form are they even talking about (DAC vs non-DAC / short-acting)? 2. Is the claim grounded in labeled evidence (human / preclinical / mechanistic / anecdote)? 3. Are they mixing research protocol language with internet protocol language? If the form isn’t specified, the timing claim is already fuzzy. Discussion When you see CJC timing advice online, do you weigh form + half-life explanations first — or community schedule charts — and why?

A COA that says 99% looks decisive. It often isn’t — until you know which question that number answered. Two different lab questions HPLC purity (often reported as a %): roughly, “of the stuff that showed up in this chromatogram, how much is the main peak?” Mass spectrometry (MS) identity: “does the molecule’s mass fingerprint match the compound you think you bought?” Those are related. They are not the same claim. Evidence label (QC literacy — not clinical) This is analytical / quality-control literacy, not a medical claim. A clean COA still does not tell you how a compound will perform in a person. Common misconception People treat “99% HPLC” as proof of identity + purity + quantity + vendor trust. Often it is only one slice of the picture — and sometimes without a clear identity method stated on the same report. Practical takeaway When you read a COA, ask separately: - Was identity confirmed (e.g. MS / matching methods), or only a purity %? - Was peptide content / quantity reported, or only purity? - Does the lot/batch on the PDF match the vial? Purity without identity is an incomplete story. Identity without lot match is still incomplete. Discussion On the last COA you actually opened: did it clearly show both an identity method and a purity result — or mostly just a big %?

Peptide Index Research Research • Testing • Transparency PEPTIDE INDEX TAKEAWAY Mazdutide is a real dual glucagon / GLP-1 peptide with strong Phase 3 data in China and a real China approval. That does not make U.S. gray-market research vials the same drug, and it does not mean FDA approval. EVIDENCE • Strong — Phase 3 efficacy in the studied Chinese populations (GLORY-1 / GLORY-2) • Moderate — U.S. Phase 2 signal only (no U.S. Phase 3 / no FDA approval as of Sept 2026) • Strong — literacy claim (China approval ≠ FDA approval ≠ research vials) WHAT IT IS • Mazdutide (IBI362 / LY3305677) is an oxyntomodulin-analogue peptide that activates both the glucagon receptor and the GLP-1 receptor • Developed with Lilly IP; Innovent holds China rights; China brand name Xinermei • Same broad dual-agonist class as survodutide — different molecule, different sponsors, different trials WHAT WE KNOW • China NMPA approved mazdutide for chronic weight management (June 27, 2025) and for glycemic control in adults with type 2 diabetes (Sept 19, 2025) • Not FDA-approved in the United States as of this check (Sept 18, 2026) • GLORY-1 Phase 3, peer-reviewed in NEJM (Chinese adults with overweight/obesity, n=610, once-weekly SC): efficacy estimand at week 48 mean weight change −12.05% (4 mg) and −14.84% (6 mg) vs −0.47% placebo (NCT05607680) • GLORY-2 Phase 3, peer-reviewed in JAMA (2026): mazdutide 9 mg mean weight change −16.65% at week 60 vs −1.50% placebo • U.S. Phase 2, peer-reviewed in The Lancet Diabetes & Endocrinology (online Aug 21, 2026; NCT06124807, n=179, no T2D): week-32 least-squares mean weight change −7.3% / −15.6% / −18.1% at 3–6 / 10 / 16 mg vs −0.9% placebo • GI side effects are the main tolerability story; higher U.S. doses had more discontinuations WHAT WE DON’T KNOW • Whether U.S. Phase 3 will match China Phase 3 or the high-dose U.S. Phase 2 signal • Long-term hard outcomes (CV events, mortality) in Western populations • What identity, purity, sterility, or dose any gray-market “mazdutide” vial actually contains

Ipamorelin shows up constantly in peptide discussions — usually next to someone else’s timing chart. Before copying a chart, it helps to separate what researchers study from internet protocol folklore. WHAT IT IS (PLAIN ENGLISH) Ipamorelin is a growth hormone–releasing peptide (GHRP-class) studied for stimulating GH release through ghrelin-pathway signaling, with a relatively selective profile in published work compared with older GHRPs. WHAT THE EVIDENCE ACTUALLY LOOKS LIKE Human data: limited / early relative to blockbuster metabolic drugs; not a large Phase 3 lifestyle literature base • Preclinical / mechanistic: stronger on receptor selectivity and GH-pulse concepts • Anecdotal / community: abundant online schedules treat as the weakest evidence tier WHY “TIMING COMES UP SO OFTEN In research discussions, Ipamorelin is often framed as short-acting relative to longer-acting GHRH analogs (for example, some CJC/DAC-style constructs people compare it to). That short-action framing is why published and lab-style conversations talk about frequency and context (fasted vs fed, stacking with a GHRH analog, overnight vs daytime) — not because there is one universal consumer schedule. Hard limit for this community: this post is educational. It is not personalized medical dosing advice. We do not prescribe “take X mg.” RESEARCH PROTOCOL VS INTERNET PROTOCOL • Research / mechanistic framing: pulse timing, half-life concepts, combination logic, what was measured in a study • Internet charts: fixed mg + clock times copied across forums with little citation If a post gives precise milligrams for you without your context, labs, or clinician oversight, that is marketing tone — not evidence literacy. PRACTICAL EDUCATIONAL TAKEAWAY When you see an Ipamorelin “schedule, ask: 1) Is this citing human, preclinical, or anecdotal sources? 2) Are they explaining why frequency matters (duration of action / pulse concept) or just listing clock times? 3) Are they separating research description from personal prescription?